Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Namilumab in chronic pulmonary sarcoidosis
NL-OMON51528Phase 2Recruiting
- Sponsor
- Kinevant Sciences
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of namilumab in Chronic Pulmonary Sarcoidosis and sarcoidosis (3 arms), sponsored by Kinevant Sciences. Primary endpoint: Mean change from baseline in percent predicted forced vital capacity. Started Jan 2023; status: recruiting.
02
Drugs
namilumab
03
Conditions
Chronic Pulmonary Sarcoidosissarcoidosis
Beyond the preview
Go deeper on NL-OMON51528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51528.